Product Launch Software Market (2026-2036)

The growth of this market is mainly driven by the institutionalisation of new product vitality as a board-reported metric, the rising volume of regulated product approvals requiring coordinated launch, expanding regulatory product data and audit trail obligations, and growing corporate research and development expenditure funding new product introduction. However, the absence of verifiable launch outcome evidence from suppliers, tightening software budget scrutiny and contracting net retention, and the continued absorption of independent suppliers into larger platforms restrain the growth of this market.

Furthermore, the rising demand for launch attribution tied to disclosed vitality reporting, the expanding requirement for product data readiness across launch markets, and the growing launch coordination requirement created by statutory compliance deadlines are expected to offer growth opportunities for the stakeholders in this market. However, launches that do not complete or do not complete on time, the opacity of supplier pricing across the supplier field, boundary overlap with general-purpose work management and adjacent categories, and fragmented product data standards with externally versioned attribute sets remain major challenges impacting the growth of this market. Additionally, rising consolidation across launch and product content software, the growing migration toward two-dimensional barcodes and digital product identity, the increasing embedding of artificial intelligence within launch workflows, and the expanding scope of launch governance into post-launch measurement are prominent trends in this market.

The Product Launch Software Market comprises the software and services used to plan, coordinate, govern and measure the commercial introduction of a product. The market includes launch planning and calendar management, launch readiness and gate management, cross-functional workstream coordination, go-to-market content and messaging management, channel, partner and field enablement for launch, launch analytics and post-launch measurement, and integrated launch management suites, together with the implementation, consulting, integration, training and managed services that deliver them. The market is measured on a software and services basis and counts purpose-built launch software and the launch modules of product management and go-to-market platforms. General-purpose work management and collaboration suites, generic business process and robotic process automation, campaign execution and marketing automation, digital asset repositories, engineering change and product lifecycle management, product information management and data syndication, regulatory submission management, and feature flagging and developer release orchestration are excluded. The market ecosystem extends from product management, product marketing and launch programme owners to software vendors, systems integrators and implementation partners, enablement and content agencies, data and analytics providers, and the standards bodies and regulators whose product compliance and disclosure obligations a launch must satisfy.

The market is experiencing strong growth as new product vitality has become a metric companies report to shareholders rather than track internally. A full-text search of the Securities and Exchange Commission filings database returns 59 filings from 22 distinct issuers using the term vitality index between 1 January 2025 and 18 October 2026, with the metric appearing in proxy statements and quarterly earnings exhibits. Equifax defines it as the percentage of revenue from new products introduced in the last three years and reported 15% for 2025 against 12% for 2024, rising to 16% for the quarter ended 30 June 2026 against a long-term goal of approximately 10%. 3M reported 284 new products launched during 2025, nearly 70% more than in 2024 and ahead of an initial target of 215, and L'Oreal reported 3,465 formulas launched. Reporting a launch cohort quarterly requires a governed launch date and a system that can attribute revenue to it.

Rising volumes of regulated product approvals are further strengthening market growth, as each authorisation begins a fixed-date commercial introduction across multiple markets. The Center for Drug Evaluation and Research approved 46 novel drugs during 2025, meeting or exceeding the user fee goal date on 44 of them, and the Center for Devices and Radiological Health authorised 124 novel devices while carrying a review workload of 4,151 premarket notifications in the 2025 financial year. The European Medicines Agency issued 104 positive opinions on human medicines during 2025, of which 38 were new active substances. The World Intellectual Property Organization recorded 3.7 million patent applications filed globally during 2024, up 4.9%, with 2.1 million grants, and the European Union Intellectual Property Office recorded 196,886 trade mark applications during 2025, up 9.1%. Each grant and registration marks a product that must eventually reach a market on a committed date.

Procurement demand is being reshaped by regulatory obligations that place compliance evidence inside the launch itself rather than alongside it. Regulation (EU) 2023/988 on general product safety entered into force on 13 December 2024, requiring a pre-market internal risk analysis and technical documentation for each product, product identification data carried both on the product and in the record, a retained audit trail of the safety decision, and an operational link from the product record to customer data so a recall can be executed and evidenced. The Ecodesign for Sustainable Products Regulation introduces digital product passport obligations on a staged basis and the Medical Device Regulation imposes unique device identification duties. Buyers are therefore specifying approval workflow, versioned product attributes and retained evidence as launch software requirements rather than as compliance system requirements.

Another major growth driver is the scale of corporate research and development expenditure, which sets the volume of products that will require commercial introduction. The European Commission Joint Research Centre recorded research and development investment of EUR 1,446 billion across the 2,000 largest corporate investors for reference year 2024, up 6.3% in nominal terms. The National Center for Science and Engineering Statistics estimated total United States research and development at USD 993.43 billion for 2024, equal to 3.39% of gross domestic product, and Eurostat recorded European Union gross domestic expenditure on research and development of EUR 403 billion, equal to 2.24%. Bosch alone reported research and development spending of EUR 7.9 billion on sales of EUR 91.0 billion, equal to 8.7% of sales. Development spending at this scale establishes a launch pipeline that must be governed years before any product ships.

Demand for market-specific product data readiness is increasingly being met through governed launch workflow rather than through product data systems alone. GS1 reports that retailers undertake 10 to 15 supplier interactions to launch each stock keeping unit and handle 15,000 inaccurate product data issues per year, while brand owners manage 700 attributes per stock keeping unit across 500 formats, within a four-layered attribute architecture that is partly jurisdiction-specific so the same product carries different mandatory attributes by region and country. The current published Global Data Synchronisation Network maintenance release is 3.1.17, dated November 2021, and more than 1,200 online marketplaces were registered in the European Union Safety Gate Portal by the end of 2025. Attribute readiness is therefore resolved per launch and per market, which places it inside the launch gate rather than in a separate data programme.

At the same time, the growing absence of verifiable supplier outcome evidence is reshaping the product launch software ecosystem and creating new opportunities for suppliers willing to publish measured results. Across approximately 60 suppliers examined, one published a time-to-market figure tied to an actual deployment, with Salsify reporting an average reduction of almost five weeks and a customer-attributed content lead time acceleration of over four weeks for a customer identified only as a large United States manufacturer of health and beauty products. No supplier in scope published an on-time launch rate, a launch cycle time or a stock keeping unit setup time. Against that, the European Medicines Agency recorded 22 withdrawn applications and 7 negative opinions during 2025 against 104 positive opinions. Buyers can measure slippage from regulators but not improvement from suppliers.

This reflects the shift of launch records from project artefacts to reporting assets, which favours suppliers able to retain launch cohorts across multi-year windows and reconcile them to financial systems.

This indicates that pricing opacity and the absence of publishable outcome evidence are pushing evaluations back toward incumbent general-purpose tools, which suppresses measured spending in the purpose-built category.

This points to market-specific attribute readiness becoming the substance of launch gating, which raises the requirement for externally versioned product data handling inside launch workflow rather than alongside it.